Quantification of biopharmaceuticals and biomarkers in complex biological matrices: A comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays

Expert Review of Proteomics

Volumn 12, Issue 4, 2015, Pages 355-374

  Bults, Peter ^a,b   Van De Merbel, Nico C ^a,b   Bischoff, Rainer ^b  

^a PRA Health Sciences   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

antibodies; biomarkers; biopharmaceuticals; ELISA; ligand binding assay; liquid chromatography; mass spectrometry; quantification; selected reaction monitoring

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; LIGAND;

BIOLOGICAL MONITORING; DEAMINATION; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; NONHUMAN; OXIDATION; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN POLYMORPHISM; RECEPTOR BINDING ASSAY; REVIEW; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; COMPARATIVE STUDY; GLYCOSYLATION; LIMIT OF DETECTION; OXIDATION REDUCTION REACTION; PROCEDURES;

ANIMALS; BIOLOGICAL PRODUCTS; BIOMARKERS; CHROMATOGRAPHY, LIQUID; GLYCOSYLATION; HUMANS; LIGANDS; LIMIT OF DETECTION; OXIDATION-REDUCTION; PROTEOLYSIS; TANDEM MASS SPECTROMETRY;

EID: 84937207812     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1050384     Document Type: Review

References (268)

1. An B, Zhang M, Qu J. Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. Drug Metab Dispos 2014;42:1858-66
2. Barton C, Kay RG, Gentzer W. Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J Proteome Res 2010;9(1):333-40
3. Becker JO, Hoofnagle AN. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/ MS. Bioanalysis 2012;4:281-90
4. Bronsema KJ, Bischoff R, Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J Chromatogr B 2012;893-894:1-14
5. Bronsema KJ, Bischoff R, van de Merbel NC. High-sensitivity LCMS/ MS quantification of peptides and proteins in complex biological samples: the impact of enzymatic digestion and internal standard selection on method performance. Anal Chem 2013;85:9528-35
6. Bystrom CE, Salameh W, Reitz R, Clarke NJ. Plasma renin activity by LCMS/ MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem 2010;56: 1561-9
7. Campbell JL, Blanc JC. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment. Bioanalysis 2011;3:645-57
8. Chappell DL, Lassman ME, McAvoy T, et al. Quantitation of human peptides and proteins via MS: review of analytically validated assays. Bioanalysis 2014;6:1843-57
9. Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum Antibodies 2009;18:47-73
10. Dawes ML, Gu H, Wang J, et al. Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion. J Chromatogr B 2013;934:1-7
11. de Dios K, Manibusan A, Marsden R, Pinkstaff J. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin. J Immunol Methods 2013;396:1-7
12. Delinsky DC, Hill KT. Quantitation of the large polypeptide glucagon by protein precipitation and LC/MS. Biomed Chromatogr 2004;18:700-5
13. Dillen L, Cools W, Vereyken L. Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides. Bioanalysis 2012;4:565-79
14. Dufield DR, Radabaugh MR. Online immunoaffinity LC/MS/MS. A general method to increase sensitivity and specificity: How do you do it and what do you need? Methods 2012;56:236-45
15. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 2011;3:1379-97
16. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 2009; 1(8):1375-88
17. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009;134: 825-34
18. Fernández Ocanã M, James IT, Kabir M, et al. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS. Anal Chem 2012;84:5959-67
19. Furlong MT, Ouyang Z, Wu S, et al. A universal surrogate peptide to enable LCMS/ MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies. Biomed Chromatogr 2012;26:1024-32
20. Furlong MT, Titsch C, Xu W, et al. An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. Bioanalysis 2014;6:1747-58
21. Furlong MT, Zhao S, Mylott W, Jenkins R. Dual universal peptide approach tobioanalysis of human monoclonal antibody protein drug candidates in animal studies. Bioanalysis 2013;5:1363-76
22. Halquist MS, Karnes HT. Quantification of Alefacept, an immunosuppressive fusion protein in human plasma using a protein analogue internal standard, trypsin cleaved signature peptides and liquid chromatography tandem mass spectrometry. J Chromatogr B 2011;879:789-98
23. Heinig K, Wirz T, Schick E, Guenzi A. Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography-tandem mass spectrometry quantitation. J Chromat A 2013;1316:69-77
24. Heudi O, Barteau S, Zimmer D, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008;80:4200-7
25. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54(11):1796-804
26. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11
27. Ji C, Sadagopan N, Zhang Y, Lepsy C. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. Anal Chem 2009;81: 9321-8
28. Ji QC, Rodila R, Gage EM, El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal Chem 2003;75:7008-14
29. Jiang H, Zeng J, Titsch C, et al. Fully validated LC-MS/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum. Anal Chem 2013;85: 9859-67
30. Kirsch S, Widart J, Louette J, et al. Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution mass spectrometry. J Chromat A 2007;1153: 300-6
31. Kleemann GR, Beierle J, Nichols AC, et al. Characterization of IgG1 immunoglobulins and peptide-Fc fusion proteins by limited proteolysis in conjunction with LC-MS. Anal Chem 2008;80:2001-9
32. Knutsson M, Schmidt R, Timmerman P. LC-MS/MS of large molecules in a regulated bioanalytical environment-which acceptance criteria to apply? Bioanalysis 2013;5:2211-14
33. Kumar V, Barnidge DR, Chen LS, et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306-13
34. Kushnir MM, Rockwood AL, Roberts WL, et al. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 2013;59:982-90
35. Lee JW, Kelley M, King LE, et al. White paper bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets : technical challenges and PK/ PD applications over the course of drug development. AAPS J 2011;13:99-110
36. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 2011;3:2459-80
37. Li H, Ortiz R, Tran L, et al. General LCMS/ MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 2012;84:1267-73
38. Li H, Ortiz R, Tran LTB, Salimi-Moosavi H. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing. AAPS J 2013;15:1267-73
39. Lin M, Lassman ME, Weiner R, Laterza OF. Development and fit-for-purpose validation of a LC-MS/MS assay for fibrinogen peptide A quantitation in human plasma. Bioanalysis 2014;6: 1759-66
40. Liu H, Manuilov AV, Chumsae C, et al. Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal Biochem 2011;414:147-53
41. Lu Q, Zheng X, McIntosh T, et al. Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Anal Chem 2009;81:8715-23
42. Mekhssian K, Mess J-N, Garofolo F. Application of high-resolution MS in the quantification of a therapeutic monoclonal antibody in human plasma. Bioanalysis 2014;6:1767-79
43. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA. Quantitative Mass Spectrometric Immunoassay of Insulin Like Growth Factor 1 research articles. J Proteome Res 2004;3:851-5
44. Nouri-Nigjeh E, Zhang M, Ji T, Yu H. Effects of Calibration Approaches on the Accuracy for LC-MS Targeted Quantification of Therapeutic Protein. Anal Chem 2014;86:3575-84
45. Nowatzke WL, Rogers K, Wells E, et al. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis 2011;3:509-21
46. Onami I, Ayabe M, Murao N, Ishigai M. A versatile method for protein-based antigen bioanalysis in non-clinical pharmacokinetics studies of a human monoclonal antibody drug by an immunoaffinity liquid chromatography-tandem mass spectrometry. J Chromat A 2014;1334:64-71
47. Pan S, Aebersold R, Chen R. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2008;8:787-97
48. Rauh M. LC-MS/MS for protein and peptide quantification in clinical chemistry. J Chromatogr B 2012;883-4
49. Sandra K, Mortier K, Jorge L, et al. LCMS/ MS quantification of next-generation biotherapeutics: A case study for an IgE binding Nanobody in cynomolgus monkey plasma. Bioanalysis 2014;6:1201-13
50. van de Merbel NC, Bronsema KJ, Nemansky M. Protein quantification using LC-MS: can it make a difference? Bioanalysis 2012;4:2113-16
51. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B 2008;872: 1-22
52. Vazvaei F, Duggan JX. Validation of LCMS/ MS bioanalytical methods for protein therapeutics. Bioanalysis 2014;6:1739-42
53. Wang Y, Qu Y, Bellows CL, et al. Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its activemetabolite in beagle and rat plasma by online SPE and LC-MS/MS. Bioanalysis 2012;4:2141-52
54. Whiteaker JR, Zhao L. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification. Mol Cell Proteomics 2010;9:184-96
55. Wilffert D, Reis CR, Hermans J, et al. Antibody-free LC-MS/MS quantification of rhTRAIL in human and mouse serum. Anal Chem 2013;85:10754-60
56. Wright K, Dufield D. Minimalistic sample preparation strategies for LC-MS quantification of large molecule biopharmaceuticals: A case study highlighting alpha-1 antitrypsin protein. Bioanalysis 2014;6:1813-25
57. Xu K, Liu L, Maia M, et al. A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study. Bioanalysis 2014;6:1781-94
58. Xu Y, Mehl JT, Bakhtiar R, Woolf EJ. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal Chem 2010;82:6877-86
59. Yang Z, Hayes M, Fang X, et al. LC-MS/ MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal Chem 2007;79:9294-301
60. Yang Z, Ke J, Hayes M, et al. A sensitive and high-throughput LC-MS/MS method for the quantification of pegylated-interferon-alpha2a in human serum using monolithic C18 solid phase extraction for enrichment. J Chromatogr B 2009;877:1737-42
61. Yuan L, Aubry A-F, Arnold ME, Ji QC. Systematic investigation of orthogonal SPE sample preparation for the LC-MS/MS bioanalysis of a monoclonal antibody after pellet digestion. Bioanalysis 2013;5:2379-91
62. Zhang Q, Spellman DS, Song Y, et al. Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies. Anal Chem 2014;86:8776-84
63. Zheng J, Mehl J, Zhu Y, et al. Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. Bioanalysis 2014;6:859-79
64. Bischoff R, Bronsema KJ, van de Merbel NC. Analysis of biopharmaceutical proteins in biological matrices by LC-MS/MS I. sample preparation. TrAC Trends Anal Chem 2013;48:41-51
65. Hopfgartner G, Lesur A, Varesio E. Analysis of biopharmaceutical proteins in biological matrices by LC-MS/MS II. LC-MS/MS analysis. TrAC Trends Anal Chem 2013;48: 52-61
66. Jungblut PR, Holzhutter HG, Apweiler R, Schluter H. The speciation of the proteome. Chem Cent J 2008;2:16
67. Schluter H, Apweiler R, Holzhutter HG, Jungblut PR. Finding one's way in proteomics: A protein species nomenclature. Chem Cent J 2009;3:11
68. Foster MW, Thompson JW, Ledford JG, et al. Identification and Quantitation of Coding Variants and Isoforms of Pulmonary Surfactant Protein A. J Proteome Res 2014;13:3722-32
69. Lisitsa A, Moshkovskii S, Chernobrovkin A, et al. Profiling proteoforms: Promising follow-up of proteomics for biomarker discovery. Expert Rev Proteomics 2014;11: 121-9
70. Yang Y, Barendregt A, Kamerling JP, Heck AJ. Analyzing protein micro-heterogeneity in chicken ovalbumin by high-resolution native mass spectrometry exposes qualitatively and semi-quantitatively 59 proteoforms. Anal Chem 2013;85: 12037-45
71. Smith LM, Kelleher NL. Proteoform: A single term describing protein complexity. Nat Methods 2013;10:186-7
72. Vegvari A, Sjodin K, Rezeli M, et al. Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring. Mol Cell Proteomics 2013;12: 2761-73
73. Liu X, Hengel S, Wu S, et al. Identification of Ultramodified Proteins Using Top-Down Tandem Mass Spectra. J Proteome Res 2013;12(12):5830-8
74. Steel LF, Haab BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J Chromatogr B 2005;815:275-84
75. Huang X, Wei Y, Li L, et al. Serum proteomics study of the squamous cell carcinoma antigen 1 in tongue cancer. Oral Oncol 2005;42:26-31
76. Yoo BS, Regnier FE. Proteomic analysis of carbonylated proteins in two-dimensional gel electrophoresis using avidin-fluorescein affinity staining. Electrophoresis 2004;25(9): 1334-41
77. Terry DE, Desiderio DM. Between-gel reproducibility of the human cerebrospinal fluid proteome. Proteomics 2003;3:1962-79
78. Garfin DE. Two-dimensional gel electrophoresis: An overview. TrAC Trends Anal Chem 2003;22:263-72
79. Caldini A, Moneti G, Fanelli A, et al. Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics 2003;3: 937-41
80. Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitations. TrAC Trends Anal Chem 2003;22:273-81
81. Galeva N, Altermann M. Comparison of one-dimensional and two-dimensional gel electrophoresis as a separation tool for proteomic analysis of rat liver microsomes: Cytochromes P450 and other membrane proteins. Proteomics 2002;2:713-22
82. Pan T, Colucci M, Wong BS, et al. Novel Differences between Two Human Prion Strains Revealed by Two-dimensional Gel Electrophoresis. J Biol Chem 2001;276: 37284-8
83. Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Nat Acad Sci 2000;97: 9390-5
84. Cordwell SJ, Nouwens AS, Verrills NM, et al. Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels. Electrophoresis 2000;21:1094-103
85. Celis JE, Gromov P. 2D protein electrophoresis: can it be perfected? Curr Opin Biotechnol 1999;10:16-21
86. Wilkins MR, Gasteiger E, Sanchez JC, et al. Two-dimensional gel electrophoresis for proteome projects: The effects of proteinhydrophobicity and copy number. Electrophoresis 1998;19:1501-5
87. Rabilloud T. Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis 1998;19:758-60
88. Packer NH, Lawson MA, Jardine DR, et al. Analyzing glycoproteins separated by two-dimensional gel electrophoresis. Electrophoresis 1998;19:981-8
89. Fountoulakis M, Takacs B, Langen H. Two-dimensional map of basic proteins of Haemophilus influenzae. Electrophoresis 1998;19:761-6
90. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Anal Biochem 1992;203:173-9
91. Schupbach J, Ammann RW, Freiburghaus AU. A universal method for two-dimensional polyacrylamide gel electrophoresis of membrane proteins using isoelectric focusing on immobilized pH gradients in the first dimension. Anal Biochem 1991;196:337-43
92. Hochstrasser DF, Harrington MG, Hochstrasser AC, et al. Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 1988;173:424-35
93. Silva JC, Gorenstein MV, Li GZ, et al. Absolute quantification of proteins by LCMSE: A virtue of parallel ms acquisition. Mol Cell Proteom 2006;5:144-56
94. Fabre B, Lambour T, Bouyssie- D, et al. Comparison of label-free quantification methods for the determination of protein complexes subunits stoichiometry. EuPA Open Proteomics 2014;4:82-6
95. Krey JF, Wilmarth PA, Shin JB, et al. Accurate label-free protein quantitation with high-and low-resolution mass spectrometers. J Proteome Res 2014;13: 1034-44
96. Ahrne E, Molzahn L, Glatter T, Schmidt A. Critical assessment of proteome-wide labelfree absolute abundance estimation strategies. Proteomics 2013;13:2567-78
97. Walsh CT. Posttranslational modifications of proteins: expanding naturés inventory. Rober Comp Publish 2006;45(7):1020
98. Bischoff R, Schlüter H. Amino acids: Chemistry, functionality and selected non-enzymatic post-translational modifications. J Proteomics 2012;75: 2275-96
99. Walsh CT, Garneau-Tsodikova S, Gatto J. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005;44:7342-72
100. Wang S, Kaltashov IA. An 18O-labeling assisted LC/MS method for assignment of aspartyl/isoaspartyl products from ASN deamidation and ASP isomerization in proteins. Anal Chem 2013;85:6446-52
101. Shimura K, Hoshino M, Kamiya K, et al. Estimation of the deamidation rates of major deamidation sites in a fab fragment of mouse IgG1-k by capillary isoelectric focusing of mutated fab fragments. Anal Chem 2013;85:1705-10
102. Nepomuceno AI, Gibson RJ, Randall SM, Muddiman DC. Accurate identification of deamidated peptides in global proteomics using a quadrupole orbitrap mass spectrometer. J Proteome Res 2013;13: 777-85
103. Palmisano G, Melo-Braga MN, Engholm-Keller K, et al. Chemical deamidation: A common pitfall in large-scale n-linked glycoproteomic mass spectrometry-based analyses. J Proteome Res 2012;11:1949-57
104. Du Y, Wang F, May K, et al. Determination of deamidation artifacts introduced by sample preparation using 18o-labeling and tandem mass spectrometry analysis. Anal Chem 2012;84:6355-60
105. Wang S, Bobst CE, Kaltashov IA. Pitfalls in protein quantitation using acid-catalyzed o18 labeling: hydrolysis-driven deamidation. Anal Chem 2011;83(18):7227-32
106. Liu M, Cheetham J, Cauchon N, et al. Protein isoaspartate methyltransferase-mediated 18o-labeling of isoaspartic acid for mass spectrometry analysis. Anal Chem 2011;84:1056-62
107. Hao P, Ren Y, Alpert AJ, Sze SK. Detection, evaluation and minimization of nonenzymatic deamidation in proteomic sample preparation. Mol Cell Proteomics 2011;10:10
108. Zhang X, Hojrup P. Cyclization of the N-Terminal X-Asn-Gly Motif during Sample Preparation for Bottom-Up Proteomics. Anal Chem 2010;82:8680-5
109. Yang H, Zubarev RA. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis 2010;31:1764-72
110. Ni W, Dai S, Karger BL, Zhou ZS. Analysis of isoaspartic acid by selective proteolysis with ASP-N and electron transfer dissociation mass spectrometry. Anal Chem 2010;82:7485-91
111. Vlasak J, Bussat MC, Wang S, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009;392:145-54
112. Sharma KK, Santhoshkumar P. Lens aging: effects of crystallins. Bio Biophy Acta 2009;1790:1095-108
113. Liu YD, van Enk JZ, Flynn GC. Human antibody Fc deamidation in vivo. Biologicals 2009;37:313-22
114. Dasari S, Wilmarth PA, Reddy AP, et al. Quantification of isotopically overlapping deamidated and 18o-labeled peptides using isotopic envelope mixture modeling. J Proteome Res 2009;8:1263-70
115. Liu H, Gaza-Bulseco G, Faldu D, et al. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008;97:2426-47
116. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol 2008;39:113-18
117. Gaza-Bulseco G, Li B, Bulseco A, Liu H. Method to differentiate ASN deamidation that occurred prior to and during sample preparation of a monoclonal antibody. Anal Chem 2008;80:9491-8
118. Krokhin OV, Antonovici M, Ens W, et al. Deamidation of-asn-gly-sequences during sample preparation for proteomics: consequences for MALDI and HPLC-MALDI analysis. Anal Chem 2006;78:6645-50
119. Hipkiss AR. Accumulation of altered proteins and ageing: causes and effects. Exp Gerontol 2006;41:464-73
120. Gupta R, Srivastava OP. Deamidation affects structural and functional properties of human {alpha}A-crystallin and its oligomerization with {alpha}B-Crystallin. J Biol Chem 2004;279:44258-69
121. Robinson NE. Protein deamidation. Proc Nat Acad Sci 2002;99:5283-8
122. Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Nat Acad Sci 2001;98:4367-72
123. Harris RJ, Kabakoff B, Macchi FD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B 2001;752:233-45
124. Carlson AD, Riggin RM. Development of improved high-performance liquid chromatography conditions for nonisotopic detection of isoaspartic acid to determineBiochem 2000;278:150-5
125. Hsu YR, Chang WC, Mendiaz EA, et al. Selective deamidation of recombinant human stem cell factor during in vitro aging: Isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers. Biochemistry 1998;37: 2251-62
126. Bischoff R, Kolbe HV. Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology. J Chromatogr B 1994;662:261-78
127. Bischoff R, Lepage P, Jaquinod M, et al. Sequence-specific deamidation: isolation and biochemical characterization of succinimide intermediates of recombinant hirudin. Biochemistry 1993;32:725-34
128. Martinez-Morillo E, Nielsen HM, Batruch I, et al. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res 2014;13: 1077-87
129. Liu H, Ponniah G, Neill A, et al. Accurate Determination of Protein Methionine Oxidation by Stable Isotope Labeling and LC-MS Analysis. Anal Chem 2013;85: 11705-9
130. Spickett CM, Pitt AR. Protein oxidation: role in signalling and detection by mass spectrometry. Amino Acids 2012;42:5-21
131. Ghesquiere B, Jonckheere V, Colaert N, et al. Redox Proteomics of Protein-bound Methionine Oxidation. Mol Cell Proteomics 2011;10:10
132. Lancellotti S, De FV, Pozzi N, et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010;48:446-56
133. Zhang H, Zielonka J, Sikora A, et al. The effect of neighboring methionine residue on tyrosine nitration and oxidation in peptides treated with MPO, H2O2, and NO2-or peroxynitrite and bicarbonate: Role of intramolecular electron transfer mechanism? Arch Biochem Biophys 2009;484:134-45
134. Rebrin I, Bregere C, Gallaher TK, Sohal RS. Detection and characterization of peroxynitrite-induced modifications of tyrosine, tryptophan, and methionine residues by tandem mass spectrometry. Methods Enzymol 2008;441:283-94
135. Shao B, Belaaouaj A, Verlinde CL, et al. Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: An oxidative mechanism for regulation of erine proteinases by myeloperoxidase. J Biol Chem 2005;280:29311-21
136. Harris RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 2005;122:117-27
137. Leichert LI, Jakob U. Protein thiol modifications visualized in vivo. PLoS Biol 2004;2:e333
138. Guan Z, Yates NA, Bakhtiar R. Detection and characterization of methionine oxidation in peptides by collision-induced dissociation and electron capture dissociation. J Am Soc Mass Spectrom 2003;14:605-13
139. Kanayama A, Inoue JI, Sugita-Konishi Y, et al. Oxidation of ikappa balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem 2002;277: 24049-56
140. Griffiths SW, King J, Cooney CL. The reactivity and oxidation pathway of cysteine 232 in recombinant human alpha 1-antitrypsin. J Biol Chem 2002;277: 25486-92
141. Griffiths SW, Cooney CL. Development of a peptide mapping procedure to identify and quantify methionine oxidation in recombinant human [alpha]1-antitrypsin. J Chromat A 2002;942:133-43
142. Stadtman ER. Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci 2001;928:22-38
143. Davis DA, Newcomb FM, Moskovitz J, et al. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. Biochem J 2000;2: 305-11
144. Jiang XSJBAEC. Identification of a MS-MS fragment diagnostic for methionine sulfoxide. J Mass Spectrom 1996;31: 1309-10
145. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med 1995;18:93-105
146. Li Y, Polozova A, Gruia F, Feng J. Characterization of the Degradation Products of a Color-Changed Monoclonal Antibody: Tryptophan-Derived Chromophores. Anal Chem 2014;86:6850-7
147. Amano M, Kobayashi N, Yabuta M, et al. Detection of Histidine Oxidation in a Monoclonal Immunoglobulin Gamma (IgG) 1 Antibody. Anal Chem 2014;86: 7536-43
148. Roeser J, Bischoff R, Bruins AP, Permentier HP. Oxidative protein labeling in mass spectrometry-based proteomics. Anal Bioanal Chem 2010;397:3441-55
149. Perdivara I, Deterding LJ, Przybylski M, Tomer KB. Mass spectrometric identification of oxidative modifications of tryptophan residues in proteins: chemical artifact or post-translational modification? J Am Soc Mass Spectrom 2010;21:1114-17
150. Bregere C, Rebrin I, Sohal RS. Detection and characterization of in vivo nitration and oxidation of tryptophan residues in proteins. Methods Enzymol 2008;441:339-49
151. Yamakura F, Ikeda K. Modification of tryptophan and tryptophan residues in proteins by reactive nitrogen species. Nitric Oxide 2006;14:152-61
152. Yamakura F, Matsumoto T, Ikeda K, et al. Nitrated and oxidized products of a single tryptophan residue in human Cu, Zn-superoxide dismutase treated with either peroxynitrite-carbon dioxide or myeloperoxidase-hydrogen peroxide-nitrite. J Biochem 2005;138:57-69
153. Fu X, Kao JLF, Bergt C, et al. Oxidative Cross-linking of Tryptophan to Glycine Restrains Matrix Metalloproteinase Activity: specific structural motifs control protein oxidation. J Biol Chem 2004;279:6209-12
154. Taylor SW, Fahy E, Murray J, et al. Oxidative post-translational modification of tryptophan residues in cardiac mitochondrial proteins. J Biol Chem 2003;278:19587-90
155. Hambly DM, Gross ML. Cold Chemical Oxidation of Proteins. Anal Chem 2009;81: 7235-42
156. Zhan X, Wang X, Desiderio DM. Mass spectrometry analysis of nitrotyrosine-containing proteins. Mass Spectrom Rev 2013. [Epub ahead of print]
157. Radi R. Protein tyrosine nitration: Biochemical mechanisms and structural basis of functional effects. Acc Chem Res 2013;46:550-9
158. Evans AR, Robinson RA. Proteomics quantification of protein nitration. Rev Analyt Chem 2013;32:173-87
159. Diaz-Moreno I, Garcia-Heredia JM, Gonzalez-Arzola K, et al. Recent methodological advances in the analysis of protein tyrosine nitration. ChemPhysChem 2013;14:3095-102
160. Butterfield DA, Dalle-Donne I. Redox proteomics. Antioxid Redox Signal 2012;17: 1487-9
161. Nuriel T, Hansler A, Gross SS. Protein nitrotryptophan: Formation, significance and identification. J Proteomics 2011;74: 2300-12
162. Aslan M, Dogan S. Proteomic detection of nitroproteins as potential biomarkers for cardiovascular disease. J Proteomics 2011;74:2274-88
163. Abello N, Kerstjens HA, Postma DS, Bischoff R. Protein Tyrosine Nitration: Selectivity, physicochemical and biological consequences, denitration and proteomics methods for the identification of tyrosine-nitrated proteins. J Proteome Res 2009;8:3222-38
164. Yeo WS, Lee SJ, Lee JR, Kim KP. Nitrosative protein tyrosine modifications: biochemistry and functional significance. BMB Reports 2008;41:194-203
165. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-Functional alteration or just a biomarker? Free Radic Biol Med 2008;45:357-66
166. Salzano AM, D'Ambrosio C, Scaloni A. Mass spectrometric characterization of proteins modified by nitric oxide-derived species. Methods Enzymol 2008;440:3-15
167. Nuriel T, Deeb RS, Hajjar DP, Gross SS. Protein 3-nitrotyrosine in complex biological samples: quantification by high-pressure liquid chromatography/ electrochemical detection and emergence of proteomic approaches for unbiased identification of modification sites. Methods Enzymol 2008;441:1-17
168. Monteiro HP, Arai RJ, Travassos LR. Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling. Antioxid Redox Signal 2008;10:843-89
169. Ischiropoulos H. Protein tyrosine nitration-An update. Arch Biochem Biophys 2008;484:117-21
170. Butterfield DA, Sultana R. Identification of 3-nitrotyrosine-modified brain proteins by redox proteomics. Methods Enzymol 2008;440:295-308
171. Butt YK, Lo SC. Detecting nitrated proteins by proteomic technologies. Methods Enzymol 2008;440:17-31
172. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007;75:291-302
173. Bartesaghi S, Ferrer-Sueta G, Peluffo G, et al. Protein tyrosine nitration in hydrophilic and hydrophobic environments. Amino Acids 2007;32:501-15
174. Ohmori H, Kanayama N. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun Rev 2005;4:224-9
175. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun 2003;305:776-83
176. Ghezzi P, Bonetto V. Redox proteomics: identification of oxidatively modified proteins. Proteomics 2003;3:1145-53
177. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003;25:295-311
178. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002;54(4):619-34
179. Sabetkar M, Low SY, Naseem KM, Bruckdorfer KR. The nitration of proteins in platelets: significance in platelet function. Free Radic Biol Med 2002;33:728-34
180. Radi R, Cassina A, Hodara R, et al. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002;33:1451-64
181. Monteiro HP. Signal transduction by protein tyrosine nitration: competition or cooperation with tyrosine phosphorylation-dependent signaling events? Free Radic Biol Med 2002;33:765-73
182. Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001;34: 541-81
183. Ischiropoulos H. Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998;356:1-11
184. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-44
185. Beck A, Bussat MC, Zorn N, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B 2005;819:203-18
186. Wiegandt A, Meyer B. Unambiguous Characterization of N-glycans of monoclonal antibody cetuximab by integration of LC-MS/MS and 1H NMR spectroscopy. Anal Chem 2014;86:4807-14
187. Váradi C, Lew C, Guttman A. Rapid magnetic bead based sample preparation for automated and high throughput N-glycan analysis of therapeutic antibodies. Anal Chem 2014;86(12):5682-7
188. Song T, Ozcan S, Becker A, Lebrilla CB. In-Depth Method for the Characterization of Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs. Anal Chem 2014;86:5661-6
189. Houel S, Hilliard M, Yu YQ, et al. N-and O-Glycosylation Analysis of Etanercept Using Liquid Chromatography and Quadrupole Time-of-Flight Mass Spectrometry Equipped with Electron-Transfer Dissociation Functionality. Anal Chem 2014;86:576-84
190. Gahoual R, Busnel JM, Beck A, et al. Full antibody primary structure and microvariant characterization in a single injection using transient isotachophoresis and sheathless capillary electrophoresis-tandem mass spectrometry. Anal Chem 2014;86:9074-81
191. Zauner G, Selman MH, Bondt A, et al. Glycoproteomic Analysis of Antibodies. Mol Cell Proteomics 2013;12:856-65
192. Patrie SM, Roth MJ, Kohler JJ. Introduction to glycosylation and mass spectrometry. Methods Mol Biol 2013;951: 1-17
193. Mao Y, Valeja SG, Rouse JC, et al. Top-down structural analysis of an intact monoclonal antibody by electron capture dissociation-fourier transform ion cyclotron resonance-mass spectrometry. Anal Chem 2013;85:4239-46
194. Leymarie N, Griffin PJ, Jonscher K, et al. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics 2013;12:2935-51
195. Tsybin YO, Fornelli L, Stoermer C, et al. Structural analysis of intact monoclonal antibodies by electron transfer dissociation mass spectrometry. Anal Chem 2011;83: 8919-27
196. Szabo Z, Guttman AS, Bones J, Karger BL. Rapid high-resolution characterization of functionally important monoclonal antibody N-glycans by capillary electrophoresis. Anal Chem 2011;83:5329-36
197. Melmer M, Stangler T, Schiefermeier M, et al. HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal Bioanal Chem 2010;398:905-14
198. Jiang H, Wu SL, Karger BL, Hancock WS. Characterization of the Glycosylation Occupancy and the Active Site in the Follow-on Protein Therapeutic: TNK-Tissue Plasminogen Activator. Anal Chem 2010;82:6154-62
199. Gil GC, Velander WH, Van Cott KE. N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon inplasma-derived and recombinant protein C. Proteomics 2009;9:2555-67
200. Borisov OV, Field M, Ling VT, Harris RJ. Characterization of oligosaccharides in recombinant tissue plasminogen activator produced in Chinese hamster ovary cells: Two decades of analytical technology development. Anal Chem 2009;81:9744-54
201. Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev 2007;26:370-88
202. Fernandez LE, Kalume DE, Calvo L, et al. Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. J Chromatogr B 2001;752:247-61
203. Werner RG, Noe W, Kopp K, Schluter M. Appropriate mammalian expression systems for biopharmaceuticals. Arzneim Fors Drug Res 1998;48:870-80
204. Fournier T, Guibourdenche J, Evain-Brion D. Review: hCGs: Different sources of production, different glycoforms and functions. Placenta 2015;36(Suppl 1): S60-5
205. Wagner-Rousset E, Bednarczyk A, Bussat MC, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B 2008;872:23-37
206. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008;9:482-501
207. Fares F. The role of O-linked and N-linked oligosaccharides on the structure-function of glycoprotein hormones: development of agonists and antagonists. Bio Biophy Acta 2006;1760:560-7
208. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005;94:1626-35
209. Gervais A, Hammel YA, Pelloux S, et al. Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency. Glycobiology 2003;13:179-89
210. Ulloa-Aguirre A, Timossi C, Damian-Matsumura P, Dias JA. Role of glycosylation in function of follicle-stimulating hormone. Endocrine 1999;11:205-15
211. Storring PL. Assaying glycoprotein hormones-the influence of glycosylation on immunoreactivity. Trends Biotechnol 1992;10:427-32
212. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1991;1:337-46
213. Cao Q, Zhao X, Zhao Q, et al. Strategy integrating stepped fragmentation and glycan diagnostic ion-based spectrum refinement for the identification of core fucosylated glycoproteome using mass spectrometry. Anal Chem 2014;86:6804-11
214. McCarthy C, Saldova R, Wormald MR, et al. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res 2014;13:3131-43
215. Ahn JM, Sung HJ, Yoon YH, et al. Integrated Glycoproteomics Demonstrates Fucosylated Serum Paraoxonase 1 Alterations in Small Cell Lung Cancer. Mol Cell Proteomics 2014;13:30-48
216. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the Identification of Glycan Biomarkers for the Detection of Cancer. Mol Cell Proteomics 2013;12: 846-55
217. Chen K, Gentry-Maharaj A, Burnell M, et al. Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res 2013;12: 1408-18
218. Wu J, Xie X, Liu Y, et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res 2012;11: 4541-52
219. Balog CI, Stavenhagen K, Fung WL, et al. N-glycosylation of colorectal cancer tissues. Mol Cell Proteomics 2012;11:571-85
220. Alley WR, Vasseur JA, Goetz JA, et al. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res 2012;11:2282-300
221. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7
222. Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007;7:4292-302
223. Li Y, Tian Y, Rezai T, et al. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem 2010;83:240-5
224. Bones J, Mittermayr S, O'Donoghue N, et al. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 2010;82: 10208-15
225. Arnold JN, Saldova R, Galligan MC, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011;10: 1755-64
226. Stanta JL, Saldova R, Struwe WB, et al. Identification of N-Glycosylation Changes in the CSF and Serum in Patients with Schizophrenia. J Proteome Res 2010;9: 4476-89
227. de Leoz ML, Young LJT, An HJ, et al. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics 2011;10:10
228. Abbott KL, Lim JM, Wells L, et al. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics 2010;10:470-81
229. Liu Y, He J, Li C, et al. Identification and Confirmation of Biomarkers Using an Integrated Platform for Quantitative Analysis of Glycoproteins and Their Glycosylations. J Proteome Res 2009;9: 798-805
230. Tang Z, Varghese RS, Bekesova S, et al. Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res 2009;9:104-12
231. Ahn YH, Lee JY, Lee JY, et al. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8:4216-24
232. Mechref Y, Hussein A, Bekesova S, et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res 2009;8: 2656-66
233. Ueda K, Fukase Y, Katagiri T, et al. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 2009;9: 2182-92
234. Kuzmanov U, Jiang N, Smith CR, et al. Differential N-glycosylation of Kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791-8
235. Matsumoto K, Shimizu C, Arao T, et al. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. J Proteome Res 2009;8: 457-62
236. Qiu Y, Patwa TH, Xu L, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 2008;7: 1693-703
237. Kaji H, Isobe T. Liquid chromatography/ mass spectrometry (LC/MS)-based glycoproteomics technologies for cancer biomarker discovery. Clin Proteomics 2008;4:14-24
238. Kreunin P, Zhao J, Rosser C, et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631-9
239. Abbott KL, Aoki K, Lim JM, et al. Targeted Glycoproteomic Identification of Biomarkers for Human Breast Carcinoma. J Proteome Res 2008;7:1470-80
240. Norton PA, Comunale MA, Krakover J, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008;104:136-49
241. Saldova R, Royle L, Radcliffe CM, et al. Ovarian Cancer is Associated With Changes in Glycosylation in Both Acute-Phase Proteins and IgG. Glycobiology 2007;17: 1344-56
242. An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res 2006;5: 1626-35
243. Yang Z, Harris LE, Palmer-Toy DE, Hancock WS. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin Chem 2006;52:1897-905
244. Comunale MA, Lowman M, Long RE, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006;5:308-15
245. Troyer DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 2004;20:117-28
246. Marian M, Seghezzi W. Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics. In: Plitnick LM, Herzyk DJ, Chapter 4 in: Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics. Academic Press; San Diego: 2013. p. 97-137
247. Bults PB, Bakker H, van de Merbel NC. In vitro and in vivo deamidation of the biopharmaceutical antibody Trastuzumab. In preparation 2015
248. Bischoff R, Clesse D, Whitechurch O, et al. Isolation of recombinant hirudin by preparative high-performance liquid chromatography. J Chromatogr B 1989;476: 245-55
249. Beck A, Sanglier-Cianferani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012;84: 4637-46
250. Leary BA, Lawrence-Henderson R, Mallozzi C, et al. Bioanalytical platform comparison using a generic human IgG PK assay format. J Immunol Methods 2013;397:28-36
251. Prudom C, Liu J, Patrie J, et al. Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels. J Clin Endocrinol Metab 2010;95:2351-8
252. Fischer SK, Yang J, Anand B, et al. The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies. mAbs 2012;4:623-31
253. Sukovaty RL, Lee JW, Fox J, et al. Quantification of recombinant human parathyroid hormone (rhPTH(1-84)) in human plasma by immunoassay: commercial kit evaluation and validation to support pharmacokinetic studies. J Pharm Biomed Anal 2006;42:261-71
254. Ouyang Z, Furlong MT, Wu S, et al. Pellet digestion: A simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis 2012;4:17-28
255. Li H, Ortiz R, Tran L, et al. General LCMS/ MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 2012;84:1267-73
256. Bronsema KJ, Schlaman R, Schalk J, et al. Development, validation and application of a quantitative LC-MS/MS method for insulin like growth factor-1 in human plasma. in preparation 2015
257. Wang SJ, Wu ST, Gokemeijer J, et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal Bioanal Chem 2012;402:1229-39
258. Cabaleiro DR, Stöckl D, Kaufman JM, et al. Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem 2006;52:1193-6
259. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-9
260. Liu Y, Buil A, Collins BC, et al. Quantitative variability of 342 plasma proteins in a human twin population. Mol Syst Biol 2015;11:1-18
261. Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach. Mol Cell Proteomics 2014;13: 907-17
262. Surinova S, Huttenhain R, Chang CY, et al. Automated selected reaction monitoring data analysis workflow for large-scale targeted proteomic studies. Nat Protoc 2013;8:1602-19
263. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012;9:555-66
264. Malmstrom L, Malmstrom J, Selevsek N, et al. Automated Workflow for Large-Scale Selected Reaction Monitoring Experiments. J Proteome Res 2012;11:1644-53
265. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MSspectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012;11:10
266. Siegel D, Meinema AC, Permentier HP, et al. Integrated quantification and identification of aldehydes and ketones in biological samples. Anal Chem 2014;86: 5089-100
267. Lesur A, Domon B. Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics 2014;15(5-6):880-90
268. Tarasow TM, Penny L, Patwardhan A, et al. Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics. Bioanalysis 2011;3: 2233-51